Handbook of Research on Techno-Entrepreneurship, Second Edition
Show Less

Handbook of Research on Techno-Entrepreneurship, Second Edition

How Technology and Entrepreneurship are Shaping the Development of Industries and Companies

Edited by François Thérin

Techno-entrepreneurship is broadly defined as the entrepreneurial and intrapreneurial activities of both existing and nascent companies operating in technology-intensive environments. This second edition examines the latest trends in techno-entrepreneurship.
Buy Book in Print
Show Summary Details
You do not have access to this content

Chapter 8: Venture capital financing of techno-entrepreneurial start-ups: drivers and barriers for investments in research-based spin-offs in the Dutch medical life sciences industry

How Technology and Entrepreneurship are Shaping the Development of Industries and Companies

Joyce Houterman, Vincent Blok and Onno Omta


With their exploitation of knowledge, technology and research results, techno-entrepreneurial spin-offs play an important role in the knowledge economy (Clarysse and Moray, 2004; Scholten, 2006). Of special importance are the start-ups and spin-offs in the biotechnology industry (together with the pharmaceuticals and medical devices part of the medical life sciences industry), which ëis one of the most booming industries at the beginning of the twenty-first centuryí (Patzelt and Brenner, 2008, p. 1). However, spin-offs/small and medium-sized enterprises (SMEs) in the medical life sciences particularly face difficulties attracting venture capital or other types of funding (Hall and Hofer, 1993; Nlemvo et al., 2002; Clarysse et al., 2005, 2007; Lockett and Wright, 2005; Lockett et al., 2005; Wright et al., 2006; Meuleman and De Maeseneire, 2012). While attracting funding is already difficult for high-tech spin-offs in general, medical life sciences spin-offs face specific funding problems. According to Patzelt and Brenner (2008, p. 2) ëmany bioentrepreneurial firms fail before they bring any product to the marketí, as the medical life sciences industry is one of the riskiest and most money-consuming industries in the modern economy. This is due to the need for large amounts of funding, combined with other industry specific characteristics such as low fixed asset ratios, complex product development cycles and high technological, market and regulatory uncertainties (Whitehead, 2002; Baeyens et al., 2006; Patzelt and Brenner, 2008).

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.